Prostate News and Research

RSS

University of Sydney's free public talk to focus on halting superbug apocalypse

Everyday activities such as kissing, touching and sharing food can lead to the spread of a new kind of superbug that is as dangerous as it is resistant.

15 Oct 2013

Study evaluates economic cost of cancer across 27 countries of the EU

The first ever study to evaluate the economic cost of cancer across the 27 countries of the EU has found that the total cost of cancer in the EU in 2009 was €126 billion, with cancer in Germany, France, Italy, and the UK together accounting for just over two-thirds of this cost (€83 billion).

15 Oct 2013

Bladder involvement can lead to prostate cancer misdiagnosis

Men with lesions in the neck, trigone, or posterior wall of the bladder should be tested for basal prostate cancer as well as bladder cancer to ensure that they are not misdiagnosed, say researchers.

14 Oct 2013

Study evaluates possibility of individualisation of castration-resistant prostate cancer management

A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.

12 Oct 2013

Resveratrol can make tumor cells more susceptible to radiation treatment

A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, follows a previous MU study that found similar results in the treatment of prostate cancer.

12 Oct 2013

Research findings may lead to new ways to combat cancer

The way cells divide to form new cells - to support growth, to repair damaged tissues, or simply to maintain our healthy adult functioning - is controlled in previously unsuspected ways UC San Francisco researchers have discovered.

12 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

Active Biotech And Hutchison China Meditech Get Rewarded

...

9 Oct 2013

$Study examines use of single-fraction radiation treatment for prostate cancer, bone metastases$

Study examines use of single-fraction radiation treatment for prostate cancer, bone metastases

Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as effective as multiple-fraction treatment with less potential for harm, has been incorporated into routine clinical practice for Medicare beneficiaries with prostate cancer and at what cost savings.

9 Oct 2013

PSA mass ratio shows prognostic power in localized prostate cancer

Research shows that pathologic prostate-specific antigen mass ratio is a significant predictor for biochemical recurrence-free survival following radical prostatectomy for localized prostate cancer in patients with negative surgical resection margins.

8 Oct 2013

Researchers use ARRAYit Microarray Platform to discover important biomarkers

ARRAYit Corporation reports today that researchers at the National Institutes of Health (NIH), National Cancer Institute (NCI) and Northeastern University have used the ARRAYit Microarray Platform to discover biomarkers important in the treatment of prostate cancer.

8 Oct 2013

Prostate cancer screening may show little benefit for old aged men

Prostate cancer screening has little benefit for men aged 75 and older, yet over three years, the Medicare fee-for-service program spent $447 million annually on PSA-based screenings-one-third of which was for men in the over 75 age group, according to study by researchers at the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center.

5 Oct 2013

New biomarker for pancreatic cancer effectively targets potential therapy for small survival rate

University of Cincinnati (UC) researchers have discovered a biomarker, known as phosphatidylserine (PS), for pancreatic cancer that could be effectively targeted, creating a potential therapy for a condition that has a small survival rate.

5 Oct 2013

J&J's Janssen Companies Launch A Trio Of Collaborations

...

3 Oct 2013

No significant association between advent of depression and subsequent advent of cancer

All of the absences from work for depression, certified by doctors, were recorded as well as many questionnaires measuring depressive moods. The results, which will be published in The American Journal of Epidemiology, do not indicate any significant association between a person experiencing the symptoms of depression during their lifetime and their subsequently contracting cancer.

2 Oct 2013

Researchers show that men experience more harm than good from routine PSA screening

Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm than good from routine PSA screening, according to research to be presented on Monday by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC2013).

1 Oct 2013